231 related articles for article (PubMed ID: 28601833)
1. Targeted simplification versus antipseudomonal broad-spectrum beta-lactams in patients with bloodstream infections due to
López-Cortés LE; Rosso-Fernández C; Núñez-Núñez M; Lavín-Alconero L; Bravo-Ferrer J; Barriga Á; Delgado M; Lupión C; Retamar P; Rodríguez-Baño J;
BMJ Open; 2017 Jun; 7(6):e015439. PubMed ID: 28601833
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial.
López-Cortés LE; Delgado-Valverde M; Moreno-Mellado E; Goikoetxea Aguirre J; Guio Carrión L; Blanco Vidal MJ; López Soria LM; Pérez-Rodríguez MT; Martínez Lamas L; Arnaiz de Las Revillas F; Armiñanzas C; Ruiz de Alegría-Puig C; Jiménez Aguilar P; Del Carmen Martínez-Rubio M; Sáez-Bejar C; de Las Cuevas C; Martín-Aspas A; Galán F; Yuste JR; Leiva-León J; Bou G; Capón González P; Boix-Palop L; Xercavins-Valls M; Goenaga-Sánchez MÁ; Anza DV; Castón JJ; Rufián MR; Merino E; Rodríguez JC; Loeches B; Cuervo G; Guerra Laso JM; Plata A; Pérez Cortés S; López Mato P; Sierra Monzón JL; Rosso-Fernández C; Bravo-Ferrer JM; Retamar-Gentil P; Rodríguez-Baño J;
Lancet Infect Dis; 2024 Apr; 24(4):375-385. PubMed ID: 38215770
[TBL] [Abstract][Full Text] [Related]
3. In
Ouranos K; Mylonakis E
Ann Intern Med; 2024 May; 177(5):JC52. PubMed ID: 38710092
[TBL] [Abstract][Full Text] [Related]
4. Role of Early De-escalation of Antimicrobial Therapy on Risk of Clostridioides difficile Infection Following Enterobacteriaceae Bloodstream Infections.
Seddon MM; Bookstaver PB; Justo JA; Kohn J; Rac H; Haggard E; Mediwala KN; Dash S; Al-Hasan MN
Clin Infect Dis; 2019 Jul; 69(3):414-420. PubMed ID: 30312362
[TBL] [Abstract][Full Text] [Related]
5. Clinical efficacy of β-lactam/β-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum β-lactamase-producing Enterobacteriaceae in haematological patients with neutropaenia: a study protocol for a retrospective observational study (BICAR).
Gudiol C; Royo-Cebrecos C; Tebe C; Abdala E; Akova M; Álvarez R; Maestro-de la Calle G; Cano A; Cervera C; Clemente WT; Martín-Dávila P; Freifeld A; Gómez L; Gottlieb T; Gurguí M; Herrera F; Manzur A; Maschmeyer G; Meije Y; Montejo M; Peghin M; Rodríguez-Baño J; Ruiz-Camps I; Sukiennik TC; Carratalà J;
BMJ Open; 2017 Jan; 7(1):e013268. PubMed ID: 28115333
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial.
Rattanaumpawan P; Werarak P; Jitmuang A; Kiratisin P; Thamlikitkul V
BMC Infect Dis; 2017 Mar; 17(1):183. PubMed ID: 28249572
[TBL] [Abstract][Full Text] [Related]
7. Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial.
Rosso-Fernández C; Sojo-Dorado J; Barriga A; Lavín-Alconero L; Palacios Z; López-Hernández I; Merino V; Camean M; Pascual A; Rodríguez-Baño J;
BMJ Open; 2015 Mar; 5(3):e007363. PubMed ID: 25829373
[TBL] [Abstract][Full Text] [Related]
8. EUropean prospective cohort study on
Gutiérrez-Gutiérrez B; Sojo-Dorado J; Bravo-Ferrer J; Cuperus N; de Kraker M; Kostyanev T; Raka L; Daikos G; Feifel J; Folgori L; Pascual A; Goossens H; O'Brien S; Bonten MJ; Rodríguez-Baño J;
BMJ Open; 2017 Apr; 7(4):e015365. PubMed ID: 28373258
[TBL] [Abstract][Full Text] [Related]
9. Multicentre randomised controlled trial to investigate usefulness of the rapid diagnostic βLACTA test performed directly on bacterial cell pellets from respiratory, urinary or blood samples for the early de-escalation of carbapenems in septic intensive care unit patients: the BLUE-CarbA protocol.
Garnier M; Gallah S; Vimont S; Benzerara Y; Labbe V; Constant AL; Siami S; Guerot E; Compain F; Mainardi JL; Montil M; Quesnel C;
BMJ Open; 2019 Feb; 9(2):e024561. PubMed ID: 30782909
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial stewardship of β-lactams in intensive care units.
Cotta MO; Roberts JA; Tabah A; Lipman J; Vogelaers D; Blot S
Expert Rev Anti Infect Ther; 2014 May; 12(5):581-95. PubMed ID: 24655303
[TBL] [Abstract][Full Text] [Related]
11. Cumulative Effect of an Antimicrobial Stewardship and Rapid Diagnostic Testing Bundle on Early Streamlining of Antimicrobial Therapy in Gram-Negative Bloodstream Infections.
Bookstaver PB; Nimmich EB; Smith TJ; Justo JA; Kohn J; Hammer KL; Troficanto C; Albrecht HA; Al-Hasan MN
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28630187
[TBL] [Abstract][Full Text] [Related]
12. Empiric Monotherapy Versus Combination Therapy for Enterobacteriaceae Bacteremia in Children.
Berkowitz NM; Spaeder MC; DeBiasi RL; Campos J; Singh N
Pediatr Infect Dis J; 2015 Nov; 34(11):1203-6. PubMed ID: 26301498
[TBL] [Abstract][Full Text] [Related]
13. Piperacillin-tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen).
Bitterman R; Koppel F; Mussini C; Geffen Y; Chowers M; Rahav G; Nesher L; Ben-Ami R; Turjeman A; Huberman Samuel M; Cheng MP; Lee TC; Leibovici L; Yahav D; Paul M
BMJ Open; 2021 Feb; 11(2):e040210. PubMed ID: 33558347
[TBL] [Abstract][Full Text] [Related]
14. Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol.
Dickstein Y; Leibovici L; Yahav D; Eliakim-Raz N; Daikos GL; Skiada A; Antoniadou A; Carmeli Y; Nutman A; Levi I; Adler A; Durante-Mangoni E; Andini R; Cavezza G; Mouton JW; Wijma RA; Theuretzbacher U; Friberg LE; Kristoffersson AN; Zusman O; Koppel F; Dishon Benattar Y; Altunin S; Paul M;
BMJ Open; 2016 Apr; 6(4):e009956. PubMed ID: 27098822
[TBL] [Abstract][Full Text] [Related]
15. Clinical Risk Score for Prediction of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Bloodstream Isolates.
Augustine MR; Testerman TL; Justo JA; Bookstaver PB; Kohn J; Albrecht H; Al-Hasan MN
Infect Control Hosp Epidemiol; 2017 Mar; 38(3):266-272. PubMed ID: 27989244
[TBL] [Abstract][Full Text] [Related]
16. Retrospective analysis comparing oral stepdown therapy for enterobacteriaceae bloodstream infections: fluoroquinolones versus β-lactams.
Mercuro NJ; Stogsdill P; Wungwattana M
Int J Antimicrob Agents; 2018 May; 51(5):687-692. PubMed ID: 29284155
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for treatment failure in patients receiving β-lactam/β-lactamase inhibitor combinations for Enterobacteriaceae bloodstream infection: A retrospective, single-centre, cohort study.
Giannella M; Pascale R; Ferraro G; Toschi A; Pancaldi L; Furii F; Bartoletti M; Tedeschi S; Ambretti S; Lewis RE; Viale P
Int J Antimicrob Agents; 2019 May; 53(5):574-581. PubMed ID: 30639527
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of β-Lactam/β-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia.
Gudiol C; Royo-Cebrecos C; Abdala E; Akova M; Álvarez R; Maestro-de la Calle G; Cano A; Cervera C; Clemente WT; Martín-Dávila P; Freifeld A; Gómez L; Gottlieb T; Gurguí M; Herrera F; Manzur A; Maschmeyer G; Meije Y; Montejo M; Peghin M; Rodríguez-Baño J; Ruiz-Camps I; Sukiennik TC; Tebe C; Carratalà J;
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28584145
[TBL] [Abstract][Full Text] [Related]
19. Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial.
Harris PN; Peleg AY; Iredell J; Ingram PR; Miyakis S; Stewardson AJ; Rogers BA; McBryde ES; Roberts JA; Lipman J; Athan E; Paul SK; Baker P; Harris-Brown T; Paterson DL
Trials; 2015 Jan; 16():24. PubMed ID: 25623485
[TBL] [Abstract][Full Text] [Related]
20. Investigator-Driven Randomised Controlled Trial of Cefiderocol versus Standard Therapy for Healthcare-Associated and Hospital-Acquired Gram-negative Bloodstream Infection: Study protocol (the GAME CHANGER trial): study protocol for an open-label, randomised controlled trial.
Wright H; Harris PNA; Chatfield MD; Lye D; Henderson A; Harris-Brown T; Donaldson A; Paterson DL
Trials; 2021 Dec; 22(1):889. PubMed ID: 34876196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
